Anming Meng | Developmental Cell Biology | Best Researcher Award |

Published on by Cell Biologist

Prof. Anming Meng | Developmental Cell Biology | Best Researcher Award

Prof. Anming Meng  , School of Life Sciences, Tsinghua University , China

Anming Meng (孟安明), born on July 22, 1963, in Dazhu County, Sichuan, China, is a renowned developmental biologist. With a bachelor’s degree in agronomy from Southwest Agricultural University in 1983, he began his career in rice breeding before shifting focus to genetics. He earned his Ph.D. in 1991 from the University of Nottingham, UK. Meng’s groundbreaking research in zebrafish embryogenesis, initiated in 1996, led to significant advancements in developmental biology. A full professor at Tsinghua University since 1998, he has contributed immensely to understanding gene regulation, cell fate, and patterning in vertebrate embryos. Meng is a member of the Chinese Academy of Sciences and TWAS, serving on various editorial boards and scientific societies. His influence is widespread, with many of his former trainees holding prominent positions in research institutions worldwide.

Publication Profile: 

Orcid

Strengths for the Award:

  1. Pioneering Research Contributions:

    • Anming Meng is a trailblazer in the field of developmental biology, particularly with his work on zebrafish embryogenesis. He has made groundbreaking discoveries, such as the identification of region-specific expression genes in zebrafish embryos and the functional roles of signaling pathways in early vertebrate development.
    • His discovery of the role of Huluwa in activating β-catenin signaling for embryonic organizer and body axis formation resolved a long-standing question in the field of developmental biology. This work has had a significant impact on our understanding of embryonic development in vertebrates.

  2. Innovative Use of Model Systems:

    • Dr. Meng’s lab was the first to establish a zebrafish lab in China, making significant contributions to the understanding of gene regulation, cell fate determination, and the mechanisms driving early embryonic development. His use of zebrafish as a model system to study these processes has been highly influential.

  3. Consistent Leadership in Research and Mentorship:

    • As a mentor, he has trained many successful researchers who now hold prominent academic and research positions worldwide. His commitment to fostering future scientific leaders is commendable, and his students have contributed significantly to developmental biology and related fields.

  4. High Impact Publications and Academic Service:

    • Dr. Meng has published numerous high-impact articles in prestigious journals, contributing to advancements in our understanding of developmental biology. Furthermore, he has played an active role in editorial boards and advisory positions, demonstrating leadership in the scientific community.
    • His role in academic societies, such as his presidency of the China Zoological Society and his contributions to the Genetics Society of China, further demonstrates his influence and commitment to advancing science in China and globally.

  5. Awards and Recognition:

    • Dr. Meng has received several prestigious awards, including the Outstanding Young Scholar Award from the Hong Kong Qiu Shi Science & Technologies Foundation and the Lifetime Accomplishment Award in Zebrafish Research. These accolades underscore the widespread recognition of his contributions to the field of developmental biology.

Areas for Improvement:

  1. Collaborative Interdisciplinary Research:

    • While Anming Meng’s work is exceptional in the domain of developmental biology, there could be more collaborative efforts with researchers from other disciplines like bioinformatics, computational biology, and material science. This could accelerate the integration of cutting-edge technologies, such as AI and CRISPR/Cas9, into his research and broaden the scope of his investigations into complex biological systems.

  2. Expanding Global Research Impact:

    • While his lab has made significant strides in the field, increasing the global outreach of his work could further elevate his contributions. This could involve more international collaborations, especially in regions where zebrafish research is in the earlier stages, as well as increasing visibility at global conferences and through open-access publications.

  3. Public Engagement and Science Communication:

    • As a leader in the field, Anming Meng could expand his impact by focusing more on science communication to a broader audience. Engaging with the public through outreach programs, online platforms, or educational content could help translate complex research into more accessible knowledge for society at large.

Education:

Anming Meng completed his undergraduate studies in 1983 at Southwest Agricultural University (now part of Southwest University), where he earned a bachelor’s degree in agronomy. His initial research focused on rice breeding. In 1987, he pursued graduate studies at the University of Nottingham, UK, under Dr. David T. Parkin, concentrating on genetic variation in wild birds using DNA fingerprinting. He earned his Ph.D. in 1991. Following this, he worked as a postdoctoral researcher at Beijing Agricultural University (now China Agricultural University), specializing in DNA fingerprinting of farm animals. Meng continued his academic journey in the U.S. as a visiting scholar at the Medical College of Georgia in 1996, working on zebrafish embryonic development in Dr. Shuo Lin’s lab. In 1998, he joined Tsinghua University as a full professor and later became a prominent figure in Chinese developmental biology.

Experience:

Anming Meng has an extensive career in both research and academia. He began as a research assistant at the National Rice Research Institute of China, before pursuing graduate studies in the UK under Dr. David T. Parkin. After earning his Ph.D. in 1991, he joined Beijing Agricultural University as a postdoctoral researcher, where he worked on DNA fingerprinting of farm animals. Meng’s pivotal shift toward zebrafish embryogenesis began in 1996 when he joined Dr. Shuo Lin’s lab at the Medical College of Georgia, USA, as a visiting scholar. In 1998, he was recruited as a full professor at Tsinghua University, where he established the first zebrafish lab in China. Over the years, Meng has led research on vertebrate embryonic development, with notable work on gene regulation and signaling pathways. He has mentored numerous successful graduates who have taken leading positions in research institutions across the globe.

Awards and Honors:

Anming Meng has received numerous prestigious awards and honors for his contributions to developmental biology. In 2000, he was named an Outstanding Young Scholar by the Hong Kong Qiu Shi Science & Technologies Foundation and received the Teaching and Research Award for University Outstanding Young Teachers from the Ministry of Education of China. Meng also won the China National Funds for Distinguished Young Scholars in 2000. He was awarded the Cheung Kong Scholar title by the Ministry of Education of China and Li Ka Shing Foundation in 2001. In 2007, he received the Ho Leung Ho Lee Foundation Prize for Science and Technology Advancement. Later awards include the Tan Jia Zhen Achievement Award in Life Sciences in 2012, the Outstanding Accomplishment Award from the Chinese Society of Cell Biology in 2020, and the Lifetime Accomplishment Award in Zebrafish Research in 2023, recognizing his remarkable impact on the field.

Research Focus:

Anming Meng’s research primarily focuses on developmental biology, with a special emphasis on zebrafish embryogenesis. His work has explored the molecular mechanisms regulating cell fate and early vertebrate patterning. Notably, he and his team have made groundbreaking discoveries in gene regulation, identifying essential signaling pathways involved in mesendoderm induction, dorsoventral patterning, and left-right asymmetry during zebrafish development. Meng’s lab pioneered the use of GFP reporters for live imaging of gene expression, contributing significantly to the study of genetic regulation in living organisms. His team also uncovered a key role for the maternal protein Huluwa in activating β-catenin signaling during embryonic axis formation, solving a longstanding question in the field. Recently, his lab’s focus has expanded to the nuclear pore complex’s clock-like function in zygotic genome activation and the role of the second polar body in mouse embryo development. Meng’s work continues to drive significant advancements in developmental and molecular biology.

Publications Top Notes:

  1. “Mapping the chromatin accessibility landscape of zebrafish embryogenesis at single-cell resolution by SPATAC-seq” 🧬🔬
  2. “Repression of MAPK/Erk signaling by Efnb2-Ephb4-Rasa1 is required for lymphatic valve formation” 💉🧪
  3. “A Golgi-derived vesicle potentiates PtdIns4P to PtdIns3P conversion for endosome fission” 📦🧫
  4. “TGFβ family signaling and development” 🧫🧬
  5. “Systematic genome editing of the genes on zebrafish Chromosome 1 by CRISPR/Cas9” 🧬🔧
  6. “Mini-III RNase-based dual-color system for in vivo mRNA tracking” 🧬💡
  7. “Sec14l3 potentiates VEGFR2 signaling to regulate zebrafish vasculogenesis” 🌱🧬
  8. “Migrasomes provide regional cues for organ morphogenesis during zebrafish gastrulation” 🧫🧠
  9. “RNA 5-Methylcytosine Facilitates the Maternal-to-Zygotic Transition by Preventing Maternal mRNA Decay” 🧬💉

Conclusion:

Anming Meng is undoubtedly a highly deserving candidate for the Best Researcher Award due to his pioneering research in developmental biology, particularly in the use of zebrafish as a model organism. His contributions have advanced our understanding of gene regulation, embryonic development, and the molecular mechanisms governing cell fate determination. As a leader, mentor, and active member of the scientific community, Dr. Meng has not only advanced the field but also nurtured the next generation of researchers. While there are areas for improvement, especially in terms of expanding collaborative efforts and public engagement, his exceptional body of work, recognition from prestigious institutions, and commitment to advancing science make him an ideal candidate for this prestigious award.

Waseem Haider | Bioinformatics | Best Paper Award

Published on by Cell Biologist

Dr. Waseem Haider | Bioinformatics | Best Paper Award

Dr. Waseem Haider , COMSATS University Islamabad , Pakistan

Dr. Waseem Haider is an Associate Professor of Bioinformatics at COMSATS University Islamabad, Pakistan, with over 25 years of teaching and research experience. He holds a Ph.D. from the University of Illinois at Urbana-Champaign, USA. As the founder and CEO of Next Gen. Solutions, a data analysis training and consultation company, he has trained over 1500 researchers in various fields, including DNA/RNA sequencing, public health data analysis, and machine learning applications. Dr. Haider’s expertise spans bioinformatics, molecular biology, and data science, utilizing tools such as R, SAS, Python, and PERL. His significant contributions include high-impact research on genetic analysis, disease monitoring, and agricultural genomics. He is passionate about applying computational methods to solve complex biological problems, enhancing public health, and advancing biotechnology.

Publication Profile:

Orcid

Strengths for the Award:

  1. Impressive Academic and Research Track Record: Dr. Haider has a wealth of experience in teaching, supervising graduate and postgraduate research, and contributing significantly to the field of bioinformatics. His supervision of over 25 MS theses and 4 PhD candidates speaks to his leadership in academic research.

  2. Wide Range of Research Interests: His research interests are diverse, covering plant biology, molecular genetics, disease diagnostics, and public health. This breadth shows that Dr. Haider is not only an expert in bioinformatics but also contributes substantially to real-world challenges in genomics and medicine.

  3. High-Impact Publications: Dr. Haider has co-authored numerous publications in reputed international journals, including high-impact ones such as PLoS One, Frontiers in Plant Science, Plant Journal, and Genes. Many of these papers tackle important issues in agriculture, biotechnology, and human health.

  4. Strong Collaboration and Networking: His collaborations with international researchers and institutions, as evidenced by his referees and joint projects, reflect his established network within the global scientific community.

  5. Practical Contribution via Next Gen. Solutions (NGS): As the founder of NGS, Dr. Haider has trained over 1,500 researchers, indicating his commitment to the practical application of bioinformatics in Pakistan and beyond. His ability to translate complex bioinformatics concepts into hands-on training is a significant strength.

  6. Cutting-Edge Research Themes: Dr. Haider’s research on RNA-Seq, genome analysis, and machine learning, as well as the application of these techniques to cancer, public health, and agricultural improvements, positions him at the forefront of modern bioinformatics research.

  7. Multidisciplinary Expertise: His ability to apply bioinformatics techniques to diverse areas (e.g., plant genomics, cancer research, disease diagnostics) demonstrates his versatility as a researcher and innovator.

Areas for Improvement:

  1. Visibility and Citation Impact: While Dr. Haider has published extensively, some of his publications might not have achieved as wide a readership or citation count as others. Increasing the visibility of his research through strategic dissemination (e.g., social media engagement, academic platforms) could enhance its impact.

  2. Focus on Recent Advancements: Although Dr. Haider is clearly active in bioinformatics, certain emerging fields, such as AI-driven personalized medicine or novel data analysis techniques, might offer opportunities to expand the scope of his work. Engaging with these newer areas could help to further strengthen his contributions to the field.

  3. Mentorship and Further Collaboration: Despite his significant supervisory role, expanding his mentorship to include more international collaborations could bring fresh perspectives and international recognition to his work. More cross-disciplinary partnerships could lead to innovative breakthroughs.

Education:

Dr. Waseem Haider’s academic journey began with a Master of Computer Science from Arid Agriculture University Rawalpindi in 2008, followed by an M.Sc/M. Phil in Biochemistry and Molecular Biology from Quaid-e-Azam University, Islamabad, in 2002. His pursuit of advanced studies culminated in a Ph.D. in Bioinformatics from the University of Illinois at Urbana-Champaign, USA, in 2014. His educational background has allowed him to bridge the gap between biology, computational sciences, and bioinformatics, shaping his research career. Dr. Haider’s extensive academic foundation enables him to supervise graduate-level research and contribute valuable insights to both the scientific community and industry. His cross-disciplinary expertise supports his role as a mentor, guiding students in bioinformatics, molecular biology, and computational biology, and fostering innovation in these fields.

Experience:

Dr. Waseem Haider has an extensive academic career, serving as a faculty member at COMSATS University Islamabad, Pakistan, since 2005. Before this, he gained experience in college-level teaching, including at Cadet College Hassan Abdal, contributing to a 25-year career in teaching and research. In addition to his academic role, he is the founder and CEO of Next Gen. Solutions (NGS), a company specializing in data analysis training and consultation. Dr. Haider has trained over 1500 researchers in bioinformatics, molecular biology, and computational techniques. His company also conducts workshops and online training sessions, providing critical skills in DNA sequencing, RNA-Seq, and machine learning. With expertise in Linux, Unix, Python, R, and PERL, Dr. Haider has applied computational methods to solve a wide range of biological problems, with his work spanning genomic research, public health, and agricultural improvements.

Research Focus:

Dr. Waseem Haider’s research focuses on applying bioinformatics and computational biology to a variety of biological fields. He specializes in DNA and RNA sequencing technologies, including genome/exome sequencing, RNA-Seq, and metagenomic data analysis. His research also extends to the application of machine learning in cancer genomics, such as RNA-Seq data analysis in cancer, and deep learning techniques in medical imaging. Additionally, Dr. Haider explores genetic variations, particularly in plant biology, and uses transcriptomic data to understand the molecular mechanisms behind disease resistance and stress tolerance in plants like soybean and canola. His work contributes to public health, especially in the analysis of infectious diseases like hepatitis and cystic echinococcosis. He has also made significant contributions to the identification of genetic biomarkers in diseases like breast cancer and diabetes. Through these research endeavors, Dr. Haider is advancing bioinformatics tools and techniques to improve healthcare and agricultural outcomes.

Publications Top Notes: 

  1. Varietal Response of Lycopersicon esculentum L. to Callogenesis and Regeneration 🍅🧬
  2. Functional and Evolutionary Characterization of the CONSTANS Gene Family in Short-Day Photoperiodic Flowering in Soybean 🌱🌾
  3. Newcastle Disease as an Emerging Disease in Peacocks of Tharparker, Pakistan 🦚🦠
  4. Sero-Prevalence of Hepatitis B and C Virus from Rural Areas of Northern Punjab (Sargodha District), Pakistan 🦠💉
  5. Evolutionary Trajectories of Duplicated FT Homologues and Their Roles in Soybean Domestication 🌿🔬
  6. Knowledge, Attitudes, and Practices Related to Cystic Echinococcosis Endemicity in Pakistan 🐑💉
  7. Transcriptome-Enabled Network Inference Revealed the GmCOL1 Feed-Forward Loop and Its Roles in Photoperiodic Flowering of Soybean 🌾🧬
  8. Knowledge, Attitudes & Practices Regarding Rabies Endemicity Among the Community Members, Pakistan 🐕💉
  9. Morpho-Ecological Study of Freshwater Mollusks of Margalla Foothills, Pakistan 🦪🏞️
  10. Protein Quantification and Enzyme Activity Estimation of Pakistani Wheat Landraces 🌾🔬

Conclusion:

Dr. Waseem Haider is undoubtedly a strong candidate for the Best Paper Award. His deep expertise, innovative research, impactful publications, and significant contributions to training researchers make him a leading figure in bioinformatics. While there are opportunities to increase the visibility of his research, his dedication to solving pressing global problems through bioinformatics and molecular biology positions him as a highly deserving candidate for recognition in the scientific community.

Ana Figueiras | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Ana Figueiras | Cancer Cell Biology | Best Researcher Award

Assist. Prof. Dr. Ana Figueiras , Faculty of Pharmacy/University of Coimbra , Portugal

Ana Rita Ramalho Figueiras is an Assistant Professor at the Faculty of Pharmacy, University of Coimbra, Portugal, and a researcher at REQUIMTE/LAQV, focusing on Pharmaceutical Technology. She earned her PhD in Pharmaceutics from the University of Coimbra in 2009, specializing in drug delivery systems, particularly for cancer treatments. Throughout her career, Ana has worked on advancing the development of block copolymers and micellar systems for targeted drug delivery. With a strong academic background and international exposure, she has contributed significantly to the fields of pharmaceutics, drug formulation, and pharmaceutical sciences. Ana’s work has been recognized through various publications in top journals, and she is deeply involved in mentoring post-doctoral researchers. Her expertise and leadership in pharmaceutical research continue to influence the development of innovative therapies in the pharmaceutical field.

Publication Profile: 

Orcid

Strengths for the Award:

Ana Rita Ramalho Figueiras is a highly accomplished researcher in pharmaceutical sciences, with extensive contributions to drug delivery systems, particularly focusing on micellar systems and polymeric micelles for cancer therapy. Her interdisciplinary work bridges pharmaceutics, chemistry, and biomedicine, showcasing her ability to innovate within drug delivery mechanisms for complex diseases. As an Assistant Professor at the University of Coimbra and an integrated member of the REQUIMTE/LAQV research group, she brings a wealth of academic and research leadership to her field.

Her innovative contributions have been recognized with various academic awards, including distinctions for oral communications and publications. Additionally, she has made substantial contributions to numerous collaborative research projects, focusing on the development of novel therapeutic strategies and drug delivery systems that target poorly soluble drugs, cancer therapies, and chronic diseases like Alzheimer’s.

Areas for Improvement:

While Figueiras is a leading figure in the scientific community, expanding her outreach to a broader range of international research collaborations could further amplify her impact. Although her work on drug delivery systems has significant potential for clinical applications, there could be further focus on translating her findings from bench to bedside by collaborating with clinical researchers for clinical trials and regulatory studies. A stronger emphasis on commercialization of her research could also be beneficial for broader societal impact.

Education:

Ana Rita Ramalho Figueiras pursued her academic journey in the field of Pharmaceutical Sciences, beginning at the University of Coimbra in Portugal. She graduated with a degree in Pharmaceutical Sciences in 2002, followed by a PhD in Pharmaceutics at the same university in 2009. Her doctoral research was focused on enhancing drug solubility and permeability, with a specific focus on cyclodextrins and mucoadhesive polymers for buccal drug delivery. During her PhD, she gained international exposure by collaborating with the University of Santiago de Compostela, Spain, and the University of Innsbruck, Austria. She is also registered as a member of the Ordem dos Farmacêuticos in Portugal since 2003. Ana’s educational foundation, combined with her interdisciplinary collaborations, has provided her with a robust understanding of pharmaceutical sciences and technologies, forming the cornerstone of her impactful career in academia and research.

Experience:

Ana Rita Ramalho Figueiras has been an Assistant Professor at the Faculty of Pharmacy, University of Coimbra, since September 2014, where she is an integrated Ph.D. member in the Pharmaceutical Technology group of REQUIMTE/LAQV. Prior to this, she was an Invited Assistant Professor from 2013 to 2014, working closely with the Center of Neuroscience and Cell Biology (CNC/UC) and contributing as a collaborator in the Health Sciences Research Centre (CICS/UBI). Her academic roles involve teaching, mentoring students and postdoctoral fellows, and leading research projects on advanced drug delivery systems. She has also been involved in supervising several postdoctoral researchers, focusing on developing and characterizing polymeric micellar systems and controlled delivery systems for drugs like pilocarpine. Throughout her career, Ana has participated in various scientific projects, bringing valuable insights into the design of innovative drug delivery platforms with applications in cancer therapy and other medical conditions.

Awards and Honors:

Ana Rita Ramalho Figueiras has received several accolades for her research excellence and contributions to the field of Pharmaceutical Sciences. In 2004, she was awarded a prestigious PhD fellowship by Fundação para a Ciência e Tecnologia (FCT), which enabled her to pursue her doctoral studies. In 2011, she received the Best Short Communication Award at the VI Annual CICS Symposium for her work on new therapeutic strategies for siRNA delivery. In 2012, she was honored with the Best Oral Communication Award for her research on Poloxamine-α-cyclodextrin supramolecular gels promoting osteogenic differentiation of mesenchymal stem cells. These awards underscore her commitment to scientific advancement, as she continues to lead innovative research in drug delivery systems, nanomedicine, and cancer therapy. Ana’s dedication to advancing pharmaceutics has also led her to mentor future generations of researchers, further solidifying her reputation as a leading academic in her field.

Research Focus:

Ana Rita Ramalho Figueiras focuses her research on developing advanced drug delivery systems, specifically in the context of cancer therapies. Her primary research interest lies in utilizing block copolymers and micellar systems for targeted and controlled drug release. This includes the formulation of poorly water-soluble drugs, improving their bioavailability, and creating novel pharmaceutical formulations for effective treatment. Ana is particularly interested in the development of polymeric micelles for the delivery of therapeutic agents, including drugs and genes, to treat various diseases, with a strong emphasis on oncology. Additionally, her research investigates the use of mucoadhesive polymers for drug delivery to mucosal surfaces. With a commitment to improving drug efficacy and reducing side effects, her work aims to enhance patient outcomes through innovative drug formulations. Ana is also involved in several projects that explore natural compounds and their potential for pharmaceutical applications, further contributing to advancements in the drug delivery and pharmaceutical fields.

Publications Top Notes:

  1. “Unraveling Rosmarinic Acid Anticancer Mechanisms in Oral Cancer Malignant Transformation” 🎗️🦷
  2. “Regulation and Safety of Cosmetics: Pre- and Post-Market Considerations for Adverse Events and Environmental Impacts” 💄⚖️
  3. “The Many Faces of Cyclodextrins within Self-Assembling Polymer Nanovehicles: From Inclusion Complexes to Valuable Structural and Functional Elements” 🔬🧪
  4. “Development and Characterization of Curcumin-Loaded TPGS/F127/P123 Polymeric Micelles as a Potential Therapy for Colorectal Cancer” 🍂⚕️
  5. “Pulmonary Delivery of Bacterial Lysates Mediated by Locust Bean Gum Microparticles” 🌬️🦠
  6. “Non-Toxic Mucoadhesive Locust Bean Gum Microparticles for Delivery of Bacterial Lysates to Prevent Respiratory Diseases” 🌱🫁
  7. “Polymersomes as the Next Attractive Generation of Drug Delivery Systems: Definition, Synthesis and Applications” 🧫💊
  8. “Nanotheranostics: The Afterglow for Cancer Immunotherapy” 💡💉
  9. “Acanthus Mollis Formulations for Transdermal Delivery: From Hydrogels to Emulsions” 🌿💧
  10. “A Review of the Application of Ganoderma Lucidum (Curtis) P. Karst. in Nanotechnology for the Treatment of Cancer” 🍄💻

Conclusion:

Ana Figueiras’ expertise in pharmaceutical technology, particularly in the development of polymeric micelles for drug delivery, marks her as an outstanding candidate for the Best Researcher Award. She is an exemplary figure in the realm of pharmaceutics with a strong research focus on improving drug therapies for cancer and other severe diseases. Her work continues to advance drug delivery systems, paving the way for future medical breakthroughs. Figueiras demonstrates a strong foundation in academic excellence, research innovation, and collaboration, positioning her as a leader in her field.

Soumya Basu | RNA Biology Function | Women Researcher Award

Published on by Cell Biologist

Dr. Soumya Basu | RNA Biology Function | Women Researcher Award

Dr. Soumya Basu , Dr. D. Y. Patil Biotechnology and Bioinformatics Institute , India

Dr. Soumya Basu, an Associate Professor and Principal Investigator at the Cancer and Translational Research Centre, Dr. D.Y. Patil Biotechnology Institute, Pune, boasts 18+ years of experience in life sciences. With a Ph.D. from Jadavpur University and expertise in cell culture, nc-RNA research, small molecule design, and drug-resistant cancer therapy, Dr. Basu is a recognized leader in cancer research. She has contributed extensively to research, scientific writing, and mentoring, with a strong track record in publications, book chapters, and protocols. Her experience spans academic positions, including roles at the Tata Memorial Centre and Chittaranjan National Cancer Institute. Dr. Basu is committed to exploring the molecular mechanisms of cancer and developing innovative therapeutic strategies, with a focus on natural product analogs and drug delivery systems targeting metastatic cancers. Her research continues to impact the understanding and treatment of cancer at a molecular level.

Publication Profile: 

Orcid

Strengths for the Award:

  1. Extensive Research Experience: Dr. Soumya Basu brings over 18 years of research experience in life sciences, with a strong focus on cancer research, small molecule design, nc-RNA research, and drug delivery systems. Her expertise in animal cell culture, cell-based assays, and molecular biology techniques demonstrates her ability to drive impactful research.

  2. Significant Academic Contribution: As a Principal Investigator at the Cancer and Translational Research Centre, Dr. Basu has made notable contributions in the area of targeted cancer therapies. Her involvement in high-impact publications, including recent journal articles and book chapters, highlights her active role in advancing scientific knowledge.

  3. Leadership and Mentorship: As an Associate Professor, Dr. Basu has shown a commitment to leadership, team management, and mentoring students and researchers. Her role as a mentor and ability to manage cross-functional teams demonstrate strong organizational and leadership skills.

  4. Scientific Writing and Publishing: Dr. Basu’s contributions to scientific literature are extensive, with multiple publications in peer-reviewed journals and book chapters. Her work on drug discovery, biomaterials, and the application of AI in drug development further illustrates her versatility and scientific rigor.

  5. Innovative Research Areas: Dr. Basu is involved in cutting-edge research areas, such as the development of natural product analogs targeting the PPAR pathway in lung carcinoma, and the design of drug delivery systems to target metastatic lymph nodes in breast cancer. Her research has the potential for significant clinical impact.

  6. Educational Background: Dr. Basu’s academic qualifications, including a Ph.D. in Life Sciences, an advanced PG course in Artificial Intelligence and Machine Learning, and an advanced diploma in Medical Writing and Regulatory Affairs, showcase her diverse skill set and adaptability to evolving scientific fields.

Areas for Improvement:

  1. Broadening Research Scope: While Dr. Basu’s focus on cancer research and small molecules is impressive, expanding her research into broader therapeutic areas or exploring more interdisciplinary fields could further strengthen her profile as a researcher. Her expertise in AI and machine learning could be leveraged further to address other diseases or health-related issues, potentially opening up new avenues for impactful research.

  2. Increase Collaborative Opportunities: While she has worked with prominent researchers, increasing international collaborations, especially in fields like artificial intelligence in biomedical research, could enhance the global impact of her work and broaden her professional network.

  3. Public Engagement and Outreach: Dr. Basu could focus on increasing public outreach and raising awareness of her research. Given her significant contributions, engaging with non-scientific audiences, through media interviews, science communication platforms, or public talks, could further highlight her as a thought leader.

Education:

Dr. Soumya Basu holds a Ph.D. in Life Sciences from Jadavpur University, where her thesis explored “Reactive oxygen species-mediated targeted therapy in drug-resistant cancer.” She furthered her academic journey with an advanced PG course in Artificial Intelligence and Machine Learning from the University of Texas at Austin, where she earned a 90% score. Dr. Basu also completed an Advanced Diploma in Medical Writing and Regulatory Affairs from Syncorp Educational Institution in Bangalore. She earned her M.Sc. in Microbiology from the University of Kalyani with a 65.6% mark and her B.Sc. (Hons.) in Physics, Chemistry, and Mathematics from the University of Burdwan. Dr. Basu’s educational background showcases a blend of biological sciences and interdisciplinary learning, equipping her with the necessary skills to tackle complex challenges in cancer research and translational medicine.

Experience:

Dr. Soumya Basu has built an illustrious academic and research career. Currently, she is an Associate Professor and Principal Investigator at Dr. D.Y. Patil Biotechnology Institute, Pune, where she has been since 2014. Dr. Basu’s academic journey includes significant roles in research, including her tenure as a Research Associate at the Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai. Her work at Chittaranjan National Cancer Institute, Kolkata, as a Senior Research Fellow (ICMR), honed her skills in cancer biology and cellular chemotherapy. Additionally, she served as a Project Assistant at Jadavpur University and the University of Calcutta, gaining foundational research experience. Her early career also included a position as a Lecturer at Kulti College. Dr. Basu’s multifaceted experience allows her to mentor students, manage cross-functional teams, and spearhead research projects in cancer and drug delivery systems.

Awards and Honors:

Dr. Soumya Basu’s dedication to research excellence has earned her numerous accolades. Her work in cancer research has led to high-impact publications in prestigious journals, with citations exceeding 550 and an H-index of 14. Dr. Basu’s expertise in drug design, nc-RNA research, and cell-based assays has contributed to the development of novel therapeutic approaches in cancer treatment. Her research collaborations have resulted in successful international publications, particularly in drug discovery and cancer genomics. Additionally, she has received recognition from academic and research institutions for her contributions to the field of cancer and biotechnology. Although specific awards are not listed, Dr. Basu’s consistent publication record and leadership in cutting-edge research demonstrate her significant influence in her field. Her recognition among peers and scientific communities highlights her as a key figure in advancing translational medicine and cancer therapy.

Research Focus:

Dr. Soumya Basu’s research primarily focuses on the molecular mechanisms of cancer and the development of innovative therapies. Her work emphasizes the design and synthesis of natural product analogs targeting the PPAR pathway in lung carcinoma and other cancers. Dr. Basu is passionate about advancing drug delivery systems, particularly those targeting metastatic lymph nodes in breast cancer. Her research also delves into non-coding RNAs (ncRNAs), exploring their roles in cancer biology and therapeutic potential. A significant portion of her work is dedicated to studying drug-resistant cancers and designing targeted therapies to overcome resistance. She is involved in both basic and applied research, aiming to develop novel, more effective cancer treatments. Dr. Basu’s interdisciplinary approach integrates artificial intelligence and machine learning techniques with biotechnological applications, positioning her as a forward-thinking scientist at the intersection of computational and experimental cancer research.

Publications Top Notes:

  1. miRVim: Three-dimensional miRNA Structure Database (2024) 🧬📚
  2. Novel insights on oral squamous cell carcinoma management using long non-coding RNAs (2024) 🦷💉
  3. Design, Docking, Synthesis, and In vitro Evaluation of Potent Anti-tubercular Agents Targeting DNA Gyrase (2024) 💊🧪
  4. Identification of Novel PPAR-β/δ Agonists from Kaempferol, Quercetin, and Resveratrol Derivatives by Targeting Cancer (2024) 🍇💥
  5. Exploring binding mode assessment of novel kaempferol, resveratrol, and quercetin derivatives with PPAR-α as potent drug candidates against cancer (2023) 🌿🔬
  6. Design, Synthesis, and Biological Evaluation of Novel Quercetin Derivatives as PPAR‐γ Partial Agonists by Modulating EMT in Lung Cancer (2023) 🍃🫀
  7. Partial Activation of PPAR‐γ by Synthesized Quercetin Derivatives Modulates TGF‐β1‐Induced EMT in Lung Cancer Cells (2023) 💊🧬
  8. Synergistic combination of ritonavir and cisplatin as an efficacious therapy in human cervical cancer cells (2023) 💊🤝
  9. Non-Coding RNAs in Oral Cancer: Emerging Roles and Clinical Applications (2023) 💉🧬

Conclusion:

Dr. Soumya Basu is a highly deserving candidate for the Research for Women Researcher Award. Her substantial research contributions, leadership roles, and innovative work in the cancer research field, particularly in drug discovery and therapeutic design, make her a standout candidate. Dr. Basu’s scientific rigor, ability to manage and mentor, and her commitment to advancing medical science position her as a leader in her field. Despite areas for further growth, particularly in expanding the scope of her research and increasing public engagement, Dr. Basu’s exemplary career trajectory, mentorship, and active research contributions make her an outstanding nominee for this prestigious award.

Huifeng Hao | Tumor pharmacology | Best Researcher Award

Published on by Cell Biologist

Dr. Huifeng Hao | Tumor pharmacology | Best Researcher Award

Dr. Huifeng Hao , Peking University Cancer Hospital , China

Dr. Huifeng Hao is an Assistant Investigator at Peking University Cancer Hospital, specializing in the integration of Chinese and Western medicine. He holds a Ph.D. from Peking University Health Science Center, where he explored Chinese-Western medical integration. His research journey began with a Bachelor’s in Clinical Medicine from Hebei Medical University. Dr. Hao has accumulated valuable postdoctoral experience at Peking Union Medical College (PUMC) in Vascular Pharmacology. His work has greatly contributed to the understanding of cancer progression, focusing on the interactions between cancer cells and vascular endothelial cells and the therapeutic effects of Traditional Chinese Medicine. With over a decade of expertise, Dr. Hao has published extensively in renowned journals, addressing critical topics in cancer research, endothelial cell function, and vascular health.

Publication Profile:

Orcid

Strengths for the Award:

  1. Extensive Educational and Research Background: Dr. Huifeng Hao has a comprehensive and solid academic foundation. With a Bachelor’s degree in Clinical Medicine from Hebei Medical University and a Ph.D. in the Integration of Chinese and Western Medicine from Peking University Health Science Center, his educational background is robust. Moreover, his postdoctoral research in Vascular Pharmacology at Peking Union Medical College significantly bolsters his expertise, particularly in vascular biology and its implications in cancer progression.

  2. Groundbreaking Research Areas: Dr. Hao’s research primarily focuses on the complex interactions between cancer cells and vascular endothelial cells, along with exploring how Traditional Chinese Medicine (TCM) can influence cancer progression. This intersection of modern pharmacology and traditional medicine offers a unique and innovative approach to cancer therapy. His studies on cancer metastasis, endothelial cell signaling, and the use of TCM as a potential therapeutic strategy for cancer represent cutting-edge work.

  3. Impressive Publication Record: Dr. Hao has co-authored numerous high-impact publications in leading journals, such as Phytomedicine, Frontiers in Pharmacology, Journal of Ethnopharmacology, and Journal of Cellular and Molecular Medicine. His work spans across critical cancer pathways, pharmacological interventions, and the exploration of novel therapeutic agents like Marsdenia Tenacissima and Berberine in combating metastasis and endothelial dysfunction.

    • His 2022 papers on the modified Bu-Fei decoction’s effects on lung metastasis and the role of CUEDC2 in promoting breast cancer progression are particularly notable for their novel findings and potential clinical applications.

  4. Collaborative and Multi-Disciplinary Research: Dr. Hao’s ability to collaborate with a wide array of experts and researchers in diverse fields demonstrates his interdisciplinary approach to solving complex scientific questions. This collaboration enhances the relevance and applicability of his work in various research areas, particularly in cancer biology, pharmacology, and integrative medicine.

  5. Pioneering Work on TCM in Cancer Therapy: Dr. Hao’s research on the role of Traditional Chinese Medicine (TCM) in cancer therapy is especially noteworthy. His studies examining how TCM influences tumor microenvironments and endothelial cell interactions provide critical insights into how integrative medicine might be leveraged to treat cancer in combination with conventional therapies. This pioneering research has the potential to redefine cancer treatments and offer patients holistic therapeutic options.

  6. Strong Impact on Cancer Research: His work on vascular pharmacology, tumor angiogenesis, and metastasis in lung cancer, particularly through the modulation of transforming growth factor beta receptors and nitric oxide signaling, has significant implications for the development of new cancer therapies. His publications are contributing valuable knowledge toward better understanding cancer progression and discovering more effective treatments.

Areas for Improvement:

  1. Broader Research Scope in Clinical Settings: While Dr. Hao’s research has focused heavily on preclinical studies, including animal models and cellular assays, expanding his research into clinical trials or human-based studies would provide essential validation for his findings. Involving clinical datasets and patient-centered research could strengthen the real-world applicability of his work.

  2. Increase in Independent Research Funding: While Dr. Hao has contributed significantly to various collaborative projects, securing independent research grants would allow him more freedom to explore his unique research hypotheses in greater depth and broaden the scope of his investigations.

  3. Expansion of International Collaborations: While Dr. Hao’s collaborations are impressive, further expanding his international network could provide additional insights and allow him to take his research to the global forefront. Partnerships with leading international cancer research institutions could also amplify the impact of his work.

Education:

  • 2004.09-2009.06: Hebei Medical University (Bachelor Degree in Clinical Medicine)
  • 2009.09-2014.06: Peking University Health Science Center (Ph.D. in Integration of Chinese and Western Medicine)
  • 2014.09-2018.08: Peking Union Medical College (Postdoctoral Training in Vascular Pharmacology)

Dr. Hao’s academic journey spans over a decade of rigorous training, blending Western scientific research with Traditional Chinese Medicine. He received his bachelor’s degree in clinical medicine and later pursued his Ph.D. in an interdisciplinary program that focused on integrating these two approaches to medicine. His postdoctoral research in vascular pharmacology furthered his expertise in understanding the physiological and molecular mechanisms of cancer-related vascular changes.

Experience:

  • 2014.09-2018.08: Postdoctoral Researcher, Peking Union Medical College, Vascular Pharmacology
  • 2018.08-Present: Assistant Investigator, Peking University Cancer Hospital, Integration of Chinese and Western Medicine

Dr. Hao’s research career spans significant academic institutions in China. During his postdoctoral research at PUMC, he specialized in vascular pharmacology, focusing on the molecular pathways involved in tumor vasculature. At Peking University Cancer Hospital, Dr. Hao continues to investigate how traditional medicine can alter the interactions between cancer cells and endothelial cells, with a goal of developing novel therapeutic strategies for cancer treatment. His interdisciplinary approach has led to multiple breakthrough discoveries in cancer biology and integrative medicine.

Research Focus:

Dr. Hao’s primary research areas include:

  • Investigating the interactions between cancer cells and vascular endothelial cells, and how these affect cancer progression
  • Exploring the role of Traditional Chinese Medicine (TCM) in regulating cancer cell interactions within the tumor microenvironment, especially with endothelial cells

By bridging the gap between modern biomedical science and traditional medicine, Dr. Hao aims to develop therapies that utilize both modalities to inhibit tumor growth and metastasis. His work focuses on understanding how TCM can modulate endothelial cells and vascular pathways, potentially leading to new treatments for cancer that are more holistic and effective.

Publications Top Notes:

  1. Modified Bu-Fei decoction inhibits lung metastasis via suppressing angiopoietin-like 4 🫁🦠
  2. CUEDC2 Drives β-Catenin Nuclear Translocation and Promotes Triple-Negative Breast Cancer Tumorigenesis 🧬💥
  3. Berberine Suppresses Lung Metastasis of Cancer via Inhibiting Endothelial Transforming Growth Factor Beta Receptor 1 🌱🏥
  4. Marsdenia tenacissima extract disturbs the interaction between tumor-associated macrophages and non-small cell lung cancer cells by targeting HDGF 🌿🧫
  5. The cyclic adenosine monophosphate elevating medicine, forskolin, reduces neointimal formation and atherogenesis in mice 🐭💉
  6. Nitric oxide, a communicator between tumor cells and endothelial cells, mediates the anti-tumor effects of Marsdenia Tenacissima Extract (MTE) 💡🔬
  7. Marsdenia tenacissima extract promotes gefitinib accumulation in tumor tissues of lung cancer xenograft mice via inhibiting ABCG2 activity 💊🔬
  8. Marsdenia tenacissima extract dilated small mesenteric arteries via stimulating endothelial nitric oxide synthase and inhibiting calcium influx 🧪🩸
  9. Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE(2) (Prostaglandin E-2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury 💥🩺
  10. Loss of Endothelial CXCR7 Impairs Vascular Homeostasis, and Cardiac Remodeling After Myocardial Infarction ❤️🫀

Conclusion:

Dr. Huifeng Hao’s contributions to cancer research, particularly the intersection of TCM and Western medicine, make him an excellent candidate for the Best Researcher Award. His innovative studies, combined with his dedication to advancing cancer treatment, position him as a leading researcher in his field. His continued research promises to significantly impact both scientific understanding and clinical practices in cancer therapy.

Chao Weng | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Mr. Chao Weng | Immunology Cellular Interactions | Best Researcher Award

Mr. Chao Weng , Renmin Hospital of Wuhan University , China

Dr. Chao Weng is an Associate Chief Physician at Renmin Hospital of Wuhan University. With both an MD and a Ph.D. from Wuhan University, he further advanced his expertise through two years of research at McGill University, Canada. Specializing in neuroimmune diseases, Dr. Weng is proficient in diagnosing and treating conditions such as multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. His prolific career spans over 40 published papers, including nearly 20 SCI-indexed articles. Dr. Weng has contributed significantly to scientific research with over nine research projects, including international collaborations, and has been awarded national patents and honors. He is an active member of prominent neurological associations, including the Neurology Branch of the China Association for the Promotion of International Exchange in Healthcare and the Wuhan Electroencephalography and Neurophysiology Association.

Publication Profile:

Orcid

Strengths for the Award:

Dr. Chao Weng is an accomplished researcher and clinician, demonstrating significant contributions to the field of neuroimmune diseases, particularly multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. His expertise in molecular mechanisms, particularly in myelin development and regeneration, is groundbreaking, as reflected in his research projects funded by prestigious organizations such as the National Natural Science Foundation of China and the Multiple Sclerosis Society of Canada. He has published over 40 academic papers, including nearly 20 SCI papers, and is actively involved in high-impact research on transcription factors, gene mutations, and the pathogenesis of various neurological conditions. His work on promoting oligodendrocyte differentiation and remyelination is highly relevant to advancing treatments for neuroimmune diseases.

In addition to his strong publication record, Dr. Weng’s leadership in hosting and participating in multiple scientific research projects, alongside his involvement in clinical education and professional organizations, demonstrates his multifaceted impact on the field. His contributions have been recognized with awards such as the second prize for scientific and technological progress in Hubei Province and a national invention patent. Furthermore, his collaborations with prestigious institutions like McGill University enhance the international scope of his work.

Areas for Improvement:

Although Dr. Weng’s research achievements are significant, continued engagement with broader interdisciplinary collaborations could further enhance the impact of his work. Integrating new technologies or methodologies in neuroimmune disease diagnostics and treatment, such as artificial intelligence or advanced imaging techniques, could provide additional depth to his ongoing projects. Furthermore, further outreach through mentorship of younger researchers could help cultivate the next generation of scientists and clinicians in his area of expertise. Expanding industry collaborations could also provide more avenues for the translation of research into clinical practice.

Education:

Dr. Chao Weng completed his MD and Ph.D. at Wuhan University, where he focused on neuroimmune diseases. Afterward, he expanded his knowledge by studying abroad at McGill University in Canada for two years. His education provided him with a strong foundation in both clinical practice and research in neuroimmunology, especially related to diseases like multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. At Wuhan University, Dr. Weng honed his expertise in molecular mechanisms of neuroimmune diseases and remyelination. His ongoing commitment to furthering scientific research in neurology and neuroimmunology has kept him at the forefront of cutting-edge advancements in his field, including in vitro human and mouse oligodendrocyte culture and transcription factor Tcf7l2’s role in oligodendrocyte differentiation.

Experience:

Dr. Chao Weng has extensive experience in the clinical diagnosis and treatment of neuroimmune diseases, particularly focusing on conditions like multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. Over the years, he has been actively involved in scientific research, completing and overseeing numerous research projects. He has led nine major scientific research projects, including collaborations with international research institutions like McGill University, Canada. Dr. Weng has published over 40 academic papers, including 20 SCI papers, contributing to the understanding of neuroimmune diseases, myelin repair, and neurodegeneration. His involvement in high-impact research, such as studying transcription factors for oligodendrocyte differentiation and remyelination, and investigating molecular mechanisms in neurological diseases, demonstrates his dedication to advancing both basic and clinical research. Additionally, he is a respected member of various neurological organizations and has received significant recognition for his scientific achievements.

Awards and Honors:

Dr. Chao Weng has earned numerous accolades for his scientific contributions, including a second prize for scientific and technological progress in Hubei Province. His groundbreaking research in neuroimmune diseases and oligodendrocyte differentiation has garnered recognition in the academic community, where he has published more than 40 peer-reviewed papers, nearly 20 of them indexed in SCI. Dr. Weng has also been awarded a national invention patent, underscoring his innovative contributions to medical science. His commitment to advancing medical knowledge and improving patient outcomes in neuroimmune diseases has positioned him as a leader in his field. His recognition extends to his role as a director of the Wuhan Electroencephalography and Neurophysiology Association and a member of the Neurology Branch of the China Association for the Promotion of International Exchange in Healthcare, which further highlights his influence and standing in the scientific and medical community.

Research Focus:

Dr. Chao Weng’s primary research focus lies in neuroimmune diseases, specifically exploring the molecular mechanisms underlying diseases like multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. His work emphasizes remyelination, the repair of myelin in neurodegenerative diseases, and the role of oligodendrocyte differentiation in central nervous system regeneration. He has spent nearly a decade investigating transcription factor Tcf7l2’s impact on myelin development and regeneration. Dr. Weng has also made significant contributions to understanding the role of β-arrestin 2 in protecting against neurological defects induced by viral infections such as herpes simplex encephalitis. Additionally, his research covers the therapeutic potential of neurotrophic factors and ion channels in various neurological disorders, including Parkinson’s disease and epilepsy. Through his work, Dr. Weng has become a key figure in bridging basic neuroscience with clinical applications, aiming to enhance diagnostic and therapeutic strategies for patients suffering from neuroimmune conditions.

Publications Top Notes:

  1. Transcription factor 7 like 2 promotes oligodendrocyte differentiation and remyelination 🧠
  2. Screening Gene Mutations in Chinese Patients With Benign Essential Blepharospasm 🔬
  3. β-Arrestin 2 protects against neurological function defects in HSV-1-induced encephalitis mice 🦠
  4. Inhibition of Acid Sensing Ion Channel 3 Aggravates Seizures by Regulating NMDAR Function ⚡
  5. Purkinje Cell Degeneration and Motor Coordination Deficits in a New Mouse Model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay 🧑‍🔬
  6. Ankfy1 is dispensable for neural stem/precursor cell development 🧬
  7. Clinical and electrophysiological evaluation of neutral wrist nocturnal splinting in patients with carpal tunnel syndrome 🤕
  8. Ring finger sensory latency difference in the diagnosis and treatment of carpal tunnel syndrome 💡
  9. Multiple and short-range cross-linking of dialdehyde carboxymethyl cellulose contributes to regulating the physicochemical property of collagen fibril 🔗
  10. Chronic inflammatory demyelinating polyneuropathy and psoriasis comorbidity with significantly alleviated symptoms after secukinumab 💊

Conclusion:

Dr. Chao Weng is undoubtedly a strong candidate for the Best Researcher Award. His consistent dedication to advancing the understanding of neuroimmune diseases, coupled with his significant contributions to the molecular mechanisms of myelin repair and regeneration, positions him as an exceptional researcher. His multidisciplinary research approach, coupled with his numerous publications and scientific innovations, speaks to his outstanding capability in the field. With continued growth in interdisciplinary collaboration and industry partnerships, Dr. Weng is well-placed to continue making profound contributions to neurology and neuroimmune disease treatments.

Hadji Djebar | Microbial Cell Biology | Best Paper Award

Published on by Cell Biologist

Prof. Hadji Djebar | Microbial Cell Biology | Best Paper Award

Prof. Hadji Djebar , saida university ,  Algeria

Dr. Djebar Hadji is a professor at Saida University, Algeria, specializing in nonlinear optical (NLO) properties, structural analysis, and theoretical quantum chemistry methods. With a deep passion for material science, his research focuses on the relationship between molecular structure and its photonic and NLO properties. Dr. Hadji has published numerous articles in top-tier scientific journals and is a recognized expert in computational chemistry, particularly within the field of nonlinear optics. His contributions extend to being an editor for BMC Chemistry, Springer, and a referee for several journals in his field. He has demonstrated significant expertise in the theoretical investigation of novel materials, combining both experimental and theoretical approaches. Dr. Hadji is continuously working on advancing the understanding of nonlinear optical properties in various molecular compounds and materials.

Publication Profile: 

Orcid

Strengths for the Award:

Dr. Djebar Hadji’s work is well-regarded in the field of Nonlinear Optical (NLO) properties, with a focus on theoretical quantum chemistry and structure-property relationships. His substantial body of work published in high-impact journals like Journal of Molecular Liquids, Journal of Electronic Materials, and Revue Roumaine de Chimie highlights his expertise in the synthesis, characterization, and theoretical study of NLO materials. Dr. Hadji’s research makes a notable contribution to understanding the photonic behavior and NLO properties of various chemical compounds, from organic to inorganic hybrids. His work on N-acyl glycine derivatives and thiosemicarbazides stands out for their novel approaches and interdisciplinary nature. Theoretical methodologies, alongside experimental validations, provide a well-rounded understanding of the materials under study. Furthermore, his continuous engagement as a reviewer and editor adds to his credibility in the scientific community.

Areas for Improvement:

While Dr. Hadji’s research has covered a broad spectrum of NLO materials, there appears to be room to increase the scope of applications and practical validations of these materials in real-world scenarios. A more applied focus, such as exploring their use in specific devices or industry-related innovations, could be beneficial for the impact and commercial potential of his work. Additionally, expanding collaborative efforts with experimentalists in material fabrication could lead to more direct applications and enhance the relevance of the research.

Education:

Dr. Djebar Hadji completed his academic journey with distinction in the field of chemistry. He earned his Ph.D. in Chemistry from a renowned Algerian institution, focusing on nonlinear optical properties and theoretical quantum chemistry methods. His academic endeavors have led him to explore various facets of computational chemistry, and he has continued to deepen his knowledge and expertise throughout his career. Dr. Hadji’s education has provided him with a robust foundation in both theoretical and experimental aspects of chemistry, which has fueled his research on understanding the complex relationships between molecular structures and their properties. His postgraduate education was complemented by ongoing professional development, where he has continuously engaged with the global scientific community through collaborations, conferences, and publications. This educational background, combined with years of teaching and research experience, has made Dr. Hadji a respected figure in his field.

Experience:

Dr. Djebar Hadji has extensive experience in academia and research. As a professor at Saida University, Dr. Hadji has mentored numerous students, guiding them through the complexities of chemistry and computational modeling. His teaching covers a wide range of topics, including theoretical quantum chemistry and nonlinear optics. Dr. Hadji is actively involved in collaborative research, having contributed to groundbreaking studies published in reputable journals such as Journal of Molecular Liquids, Journal of Electronic Materials, and Physical Chemistry Research. His research spans the theoretical and computational investigation of nonlinear optical properties, focusing on the structure-property relationships in various chemical compounds. Dr. Hadji also holds editorial roles in prominent journals and reviews papers for several renowned scientific publications. His multifaceted experience, including both theoretical and experimental work, positions him as a highly knowledgeable and influential figure in the field of chemistry, particularly in nonlinear optics and material science.

Research Focus:

Dr. Djebar Hadji’s research primarily focuses on nonlinear optical (NLO) properties, the interaction between molecular structures and photonic characteristics, and the application of theoretical quantum chemistry methods. His work investigates how molecular arrangements and electronic properties influence NLO responses, which has vast applications in areas like telecommunications, photonics, and material science. Dr. Hadji’s research explores novel molecular compounds, particularly those with potential for high-performance NLO behavior. He utilizes quantum chemical methods such as DFT (Density Functional Theory) and TD-DFT (Time-Dependent DFT) to predict and analyze molecular properties. Additionally, Dr. Hadji is dedicated to the synthesis and characterization of new materials, including hybrid inorganic-organic systems and azo derivatives. His goal is to design materials with enhanced NLO properties for various technological applications, focusing on optimizing the relationship between structure and function. This research contributes significantly to the development of advanced materials with improved nonlinear optical responses.

Publications Top Notes:

  1. Nonlinear optical and antimicrobial activity of N-acyl glycine derivatives, Journal of Molecular Liquids, 2024 📖🧬
  2. Deeper Insights on the Nonlinear Optical Properties of O-acylated Pyrazoles, Journal of Electronic Materials, 2024 🔬💡
  3. Synthesis And Characterization Of Novel Thiosemicarbazide For Nonlinear Optical Applications: Combined Experimental And Theoretical Study, Revue Roumaine de Chimie, 2024 🔬⚗️
  4. NLO azo compounds with sulfonamide groups: A theoretical investigation, Journal of Indian Chem. Soc., 2023 🧪✨
  5. Synthesis and characterization of novel thiosemicarbazide for nonlinear optical applications, Rev. Roum. Chim., 2023 ⚗️🔍
  6. Efficient NLO Materials Based on Poly(ortho-anisidine) and Polyaniline: A Quantum Chemical Study, Journal of Electronic Materials, 2022 🧬💡
  7. Molecular Structure, Linear, and Nonlinear Optical Properties of Piperazine-1,4-Diium Bis 2,4,6-Trinitrophenolate, Physical Chemistry Research, 2022 ⚗️📚
  8. Theoretical insights into the nonlinear optical properties of cyclotriphosphazene, Journal of Materials Science, 2022 📊🔬
  9. Linear and nonlinear optical properties of anhydride derivatives: A theoretical investigation, December 2021 🧪💡
  10. Synthesis, spectroscopic characterization, crystal structure, and linear/NLO properties of a new hybrid compound, Journal of Molecular Structure, 2021 🧪🔍

Conclusion:

Dr. Djebar Hadji’s extensive contribution to the understanding of nonlinear optical properties of various compounds places him as a strong candidate for the Research for Best Paper Award. His solid foundation in both experimental and theoretical aspects of material science and quantum chemistry, as well as his consistent publication record, are commendable. While his work is theoretically rich, adding practical application studies could further enhance his impact and lead to real-world implementation of his discoveries in the field of optics and photonics.

Xue Li | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Xue Li | Cancer Cell Biology | Best Researcher Award

Dr. Xue Li , Institute of Chemistry Chinses Academy of Sciences , China

Dr. Xue Li is an Assistant Researcher at the Institute of Chemistry, Chinese Academy of Sciences, specializing in the design and application of functional carbon nanomaterials in biomedical fields. She holds a Bachelor’s degree from Sichuan University (2009-2013) and a PhD from the Institute of Chemistry, Chinese Academy of Sciences (2013-2018). Since 2018, Dr. Li has contributed significantly to the development of nanomaterial-based therapies for various diseases, particularly focusing on cancer, diabetes, and neurodegenerative diseases. Her work is characterized by innovative approaches to developing fullerene-based nanoparticles for therapeutic purposes. Dr. Li has published extensively in high-impact journals and is a recognized leader in her field, collaborating with national and international experts to drive forward the potential of nanomaterials in medicine.

Publication Profile:

Orcid

Strengths for the Award:

Dr. Xue Li stands out for her groundbreaking research on the design and biomedical application of functional carbon nanomaterials, particularly fullerenes, for treating complex diseases. Her work explores innovative therapeutic strategies, such as targeting inflammation, oxidative stress, and immune responses to address conditions like cancer, diabetes, and neurodegenerative diseases. Dr. Li has authored multiple high-impact journal publications, demonstrating her deep expertise in nanomaterials and their integration into medical treatments. Her contributions, such as reducing neuroinflammation to alleviate Parkinson’s disease and mitigating immune-mediated liver injury, showcase her ability to translate scientific knowledge into real-world solutions. Dr. Li’s collaborative approach and her role in advancing nanomedicine highlight her as a leading figure in her field.

Areas for Improvement:

While Dr. Li’s work is exceptional, expanding her research into more diverse therapeutic areas, such as cardiovascular diseases or neurodegenerative conditions like Alzheimer’s, could further broaden the impact of her research. Additionally, exploring the scalability and commercialization of her nanomaterial-based therapies would be a valuable direction for future development.

Education:

Dr. Xue Li completed her Bachelor’s degree in Chemistry at Sichuan University in June 2013. She pursued her Ph.D. at the Institute of Chemistry, Chinese Academy of Sciences, from 2013 to 2018, focusing on the design and application of nanomaterials, particularly fullerenes, for medical applications. During her doctoral studies, she gained significant experience in the synthesis, functionalization, and biomedical use of carbon nanomaterials. Dr. Li’s research laid the foundation for her current work as an Assistant Researcher at the Institute of Chemistry, Chinese Academy of Sciences, a position she has held since 2018.

Experience:

Dr. Xue Li has worked extensively in the field of nanomaterials, contributing to significant advancements in the application of fullerene-based nanoparticles for biomedical purposes. Since 2018, she has been an Assistant Researcher at the Institute of Chemistry, Chinese Academy of Sciences, where her research focuses on the development of functional nanomaterials for the treatment of diseases such as cancer, diabetes, and neurodegenerative disorders. Dr. Li has worked on several high-impact projects, including designing inflammation-targeting nanoparticles and investigating their roles in regulating immune responses and improving disease outcomes. Her experience spans both experimental techniques in nanomaterial synthesis and in vivo therapeutic applications. Additionally, Dr. Li has collaborated with multiple research institutions globally and has been recognized for her contributions to advancing nanomedicine.

Research Focus:

Dr. Xue Li’s research focuses on the design, synthesis, and biomedical applications of functional carbon nanomaterials, particularly fullerenes and their derivatives. Her work aims to develop innovative therapeutic strategies, leveraging the unique properties of these nanomaterials to address complex medical challenges, including cancer, autoimmune diseases, and neurodegenerative disorders. She is particularly interested in creating nanoparticles that target specific cellular pathways, such as inflammation and oxidative stress, to improve therapeutic outcomes. Dr. Li’s research includes the development of nanoparticles that can modulate macrophage differentiation and mitigate conditions like rheumatoid arthritis, autoimmune hepatitis, and neuroinflammation. By focusing on the functionalization of fullerenes, her work also explores how these materials can be used to treat insulin resistance and neurodegenerative diseases such as Parkinson’s.

Publications Top Notes:

  1. 🧬 Fullerenols hijack lysosomes to disrupt inter-organellar crosstalk and block autophagy pre-activated by mTOR inhibitors for cancer cell PANoptosis. Sci. Bull. 2025
  2. 💊 Inflammation-targeting fullerene nanoparticles dually inhibit macrophage and osteoclast differentiation for mitigating rheumatoid arthritis. CCS Chem. 2024
  3. 🔬 Curdlan decorated fullerenes mitigate immune-mediated hepatic injury for autoimmune hepatitis therapeutics via reducing macrophage infiltration. ACS Appl. Mater. Interfaces 2024
  4. 💡 The application of nanomaterials in the treatment of pancreatic-related diseases. Int. J. Mol. Sci. 2024
  5. 🧠 Oral [60] fullerene reduces neuroinflammation to alleviate Parkinson’s disease via regulating gut microbiome. Theranostics 2023
  6. 🍏 Dual regulation on oxidative stress and endoplasmic reticulum stress by [70] fullerenes for reversing insulin resistance in diabetes. Nano Today 2022
  7. 🔬 Gadofullerene Nanoparticles Extend Survival Rate and Down-Regulate Thrombin Expression in Orthotopic Pancreatic Cancer. Sci. China Mater. 2022
  8. 🩸 Gadofullerene Nanoparticles Reverse Dysfunctions of Pancreas and Improve Hepatic Insulin Resistance for Type 2 Diabetes Mellitus Treatment. ACS Nano 2019
  9. 🌱 Biomaterials: Application of Nanomaterials in the Treatment of Pancreatic-Related Diseases. Biomaterials 2018

Conclusion:

Dr. Xue Li’s exceptional research on functional nanomaterials and their applications in medicine, particularly in cancer, autoimmune diseases, and neurodegeneration, makes her a strong contender for the Research for Best Researcher Award. Her innovative approaches, contributions to high-impact journals, and dedication to advancing nanomedicine provide a solid foundation for future breakthroughs.

Chang Feng | Cancer Cell Biology | Best Researcher Award

Published on by Cell Biologist

Dr. Chang Feng | Cancer Cell Biology | Best Researcher Award

Dr. Chang Feng , Shanghai University , China

Chang Feng is a distinguished researcher in the fields of tumor molecular diagnosis, biosensing, and intelligent DNA. Born in Shanghai, China, on January 1, 1988, Chang Feng pursued a rigorous academic journey, completing his Ph.D. at Nanjing University (2015-2019) after earning his M.D. from Shanghai University (2012-2015). He is currently a lecturer at Shanghai University since 2019. Feng has contributed significantly to scientific advancements in cancer diagnostics, molecular biosensors, and cutting-edge DNA research. His works often involve the development of innovative detection techniques and the creation of novel DNA-based diagnostic systems. Feng has a collaborative approach, working with multiple researchers to achieve groundbreaking results. His publications in prestigious journals highlight his expertise in developing biosensors, RNA origami, and catalytic DNAzymes for biomedical applications.

Publication Profile: 

Scopus

Strengths for the Award:

Chang Feng’s research is exceptional and well-suited for the Best Researcher Award. His expertise spans across tumor molecular diagnosis, biosensor development, and intelligent DNA systems. His contributions to cancer diagnostics, bioimaging, and biosensing technologies are groundbreaking. Feng has published several high-impact articles in leading journals, demonstrating significant advancements in DNAzymes, electrochemical biosensing, and RNA origami. His work in designing innovative DNA-based diagnostic platforms and cancer therapies reflects his ability to integrate chemistry, biology, and engineering, providing novel solutions for clinical applications. Feng’s interdisciplinary approach and leadership in the field have earned him numerous collaborations with researchers and institutions globally, further enhancing his credibility as a top-tier researcher.

Areas for Improvements:

While Feng has made remarkable contributions to scientific research, one area for improvement is expanding his focus to more clinical applications of his findings. Commercializing his biosensing technologies for real-world healthcare implementation would increase the practical impact of his work. Additionally, improving outreach through public science communication could help raise awareness of his advancements and engage a broader audience.

Education:

Chang Feng received his M.D. from Shanghai University in 2015, where he developed a strong foundation in molecular biology, diagnostics, and bioengineering. His doctoral journey continued at Nanjing University (2015-2019), where he obtained his Ph.D. focusing on tumor molecular diagnosis and biosensing technologies. During his time at Nanjing University, Feng’s research concentrated on the development of DNA-based biosensors and new methodologies for cancer detection. His education at these esteemed institutions provided him with the technical expertise necessary to pioneer groundbreaking research in the field of molecular diagnostics. Feng’s academic training involved rigorous coursework in molecular biology, chemical engineering, and bioinformatics, contributing significantly to his current work in bioimaging, biosensing, and the development of intelligent DNA systems.

Experience:

Chang Feng has a strong academic and research career, currently serving as a lecturer at Shanghai University since 2019. Prior to his current role, he earned his Ph.D. at Nanjing University (2015-2019) and M.D. from Shanghai University (2012-2015). Throughout his career, Feng has collaborated with leading researchers, contributing to the development of innovative biosensing technologies and cancer diagnostics. His work includes advancing DNA-based biosensors, DNAzyme probes, and other cutting-edge diagnostic tools. As a lecturer, Feng mentors graduate students and participates in academic teaching and research projects. He has been involved in several collaborative publications that have furthered the field of molecular biosensors, focusing on intelligent DNA-based systems and tumor detection methodologies. Feng’s research experience combines theoretical knowledge with practical applications, making him a recognized figure in the field of biosensor research and molecular diagnostics.

Research Focus:

Chang Feng’s primary research focus lies in tumor molecular diagnosis, biosensor development, and intelligent DNA systems. He is particularly interested in advancing technologies for cancer detection through the application of molecular biosensors, bioimaging, and intelligent DNA devices. His research explores the use of DNAzymes, catalytic DNA molecules, and RNA origami for targeted molecular detection, with a focus on enhancing the sensitivity and specificity of cancer diagnostics. Feng’s work also investigates the use of biosensors for the detection of small molecules, leveraging innovative electrochemical and fluorescence-based platforms. His interdisciplinary approach combines elements of chemistry, biology, and engineering to create advanced diagnostic systems with potential clinical applications. Feng is dedicated to improving the efficiency of diagnostic tools and is committed to developing more accurate and faster methods for early cancer detection and molecular analysis.

Publications Top Notes:

  1. Single-cell analysis of highly metastatic circulating tumor cells by combining a self-folding induced release reaction with a cell capture microchip 🧬🔬 (Anal. Chem., 2021)
  2. Hierarchical biomarkers detection via a universal polydopamine probe catalyzed by a hexagonal star-nanostructured DNAzyme 🔬🧪 (Sensor. Actuat. B-Chem., 2022)
  3. Construction of a ternary complex based DNA logic nanomachine for a highly accurate imaging analysis of cancer cells 🧬💡 (ACS Sens., 2020)
  4. Lantern-shaped flexible RNA origami for Smad4 mRNA delivery and growth suppression of colorectal cancer 🧬🦠 (Nat. Commun., 2023)
  5. Liquid-colloid-solid modular assembly for three-dimensional electrochemical biosensing of small molecules 💧⚡ (Biosens. Bioelectron., 2024)
  6. Dual-targets binding protection mediated rolling circle transcription with tandem fluorescent RNA aptamers for label-free detection of liver cancer biomarkers 🧬🦠 (Sensor. Actuat. B-Chem., 2024)
  7. Cell-Free Biosensing Genetic Circuit Coupled with Ribozyme Cleavage Reaction for Rapid and Sensitive Detection of Small Molecules 🧬⚡ (ACS Synth. Biol., 2023)
  8. A portable and partitioned DNA hydrogel chip for multitarget detection 💧🧬 (Lab Chip., 2023)

Conclusion:

Chang Feng’s research in tumor molecular diagnostics, biosensors, and intelligent DNA is truly cutting-edge. His scientific rigor, collaboration with top researchers, and groundbreaking discoveries in cancer detection and biosensing technologies make him a deserving candidate for the Best Researcher Award. By continuing to bridge the gap between laboratory research and clinical applications, Feng will likely have an even greater impact in advancing medical diagnostics and therapeutic strategies.

Prbhu Narayan Meena | Host-Pathogen Interactions | Best Paper Award

Published on by Cell Biologist

Dr. Prbhu Narayan Meena | Host-Pathogen Interactions | Best Paper Award

Dr. Prbhu Narayan Meena , ICAR-NRIIPM, New delhi , India

Dr. P. N. Meena, M.Sc. (Ag), Ph.D., is a renowned Scientist in the field of Plant Pathology. With a career that began in 2013 at ICAR-CRIJAF, Kolkata, Dr. Meena played a crucial role in developing two varieties of kenaf resistant to foot and stem rot disease. Over the years, Dr. Meena has made significant contributions to plant pathology research, publishing 7 international and 27 national research papers, 12 abstracts, 2 books/compendiums, and numerous other scientific works. She has delivered over 13 invited lectures, organized several farmer field schools, and participated in 22 trainings and conferences. Her research has earned her awards, including the Best Plant Pathologist Award in 2019 and 2024. Dr. Meena’s work continues to benefit horticulture, fibre, and pulse crops through innovative disease management solutions.

Publication Profile:

Google Scholar

Strengths for the Award:

  1. Outstanding Contributions to Plant Pathology: Dr. P. N. Meena has made significant contributions to plant pathology research, particularly in the development of disease-resistant crops and bio-control strategies. Her work on kenaf varieties resistant to foot and stem rot disease, and her extensive publications on molecular detection and disease management strategies, are impressive achievements that underscore her excellence in the field.

  2. Comprehensive Research Focus: Dr. Meena has worked across multiple aspects of plant disease management, including molecular diagnostics, eco-friendly management practices, and bio-control agents like Trichoderma harzianum, Bacillus subtilis, and Pseudomonas fluorescens. This broad research focus ensures her work impacts horticulture, fibre crops, and pulses.

  3. Recognition & Awards: She has received prestigious awards such as the Best Plant Pathologist Award in 2019 and 2024, highlighting her esteemed position in the research community.

  4. Extensive Publication Record: With over 7 international papers, 27 national papers, 2 books, 13 book chapters, and numerous abstracts and technical bulletins, Dr. Meena has demonstrated a prolific research output. Her works are valuable for both academia and practical applications in agriculture.

  5. Leadership & Community Engagement: Dr. Meena has played a leadership role in organizing numerous farmer training programs, field schools, and workshops. This active engagement with the farming community, along with her work in disseminating scientific knowledge, strengthens her candidacy for the award.

Areas for Improvement:

  1. Collaborative Research in Emerging Fields: While Dr. Meena has a strong background in traditional crop disease management, there is potential to expand her research into emerging fields like genomic data integration and precision agriculture. Collaborations with experts in genomics or climate change could open new avenues for disease resistance and crop resilience.

  2. Expansion in Global Research Networks: While her contributions are highly recognized nationally and regionally, further involvement in international research collaborations, especially with top global agricultural institutions, could elevate the global impact of her research.

  3. Publication of Research in High-Impact Journals: Though Dr. Meena’s publication record is commendable, focusing more on high-impact international journals could further boost the visibility of her work on a global scale, ensuring that her research reaches a wider, more diverse audience.

Education:

Dr. P. N. Meena pursued her Master’s in Science (Agriculture) with a specialization in Plant Pathology and later completed her Ph.D. in the same field. Her academic journey has been marked by an unwavering commitment to understanding plant diseases and finding sustainable solutions. Her advanced education laid the foundation for her impactful research at ICAR-CRIJAF, where she actively contributed to various projects focused on disease resistance in crops. Throughout her educational career, Dr. Meena has exhibited excellence, being well-versed in molecular detection and plant disease management. Her knowledge has allowed her to develop various technologies in disease management strategies, particularly for horticultural and fibre crops. She has remained engaged with both national and international research communities, collaborating extensively to share insights and expertise.

Experience:

Dr. P. N. Meena began her career as a Scientist (Plant Pathology) at ICAR-CRIJAF, Kolkata, in 2013, where she made notable contributions to the development of kenaf varieties resistant to major diseases. Her extensive experience includes publishing 7 international and 27 national research papers, authoring 2 books, and developing 21 technologies for disease management. Dr. Meena has served as a Co-PI in 2 externally funded projects, PI in 2 institute projects, and Co-PI in 14 institute projects. She has delivered 14 oral/poster presentations and 13 invited lectures in farmer training programs. Her leadership is reflected in organizing 18 farmer field schools (FFS) and coordinating 5 FLDs. Dr. Meena has received multiple awards for her contribution to plant pathology, including the Best Plant Pathologist Award in 2019 and 2024. Her active involvement in conferences, workshops, and research continues to influence the agricultural community.

Research Focus:

Dr. P. N. Meena’s research focus primarily revolves around plant diseases, particularly in horticultural, fibre, and pulse crops. Her groundbreaking work includes developing molecular detection technologies for various plant pathogens and strategies for managing diseases like foot and stem rot in crops. A significant part of her research is centered on eco-friendly disease management, using bioagents such as Trichoderma harzianum, Bacillus subtilis, and Pseudomonas fluorescens. Additionally, she is passionate about exploring host plant resistance, disease diagnostics, and sustainable agricultural practices. Dr. Meena’s work extends to protecting crops like jute and groundnut from harmful pathogens, improving yield, and promoting environmental sustainability. With 21 technologies developed in disease management and ongoing research in biocontrol, her work contributes substantially to integrated pest management (IPM). Her research also involves extensive work in genetic diversity and the development of resistant crop varieties.

Publications Top Notes:

  1. Biocontrol activity of Trichoderma harzianum, Bacillus subtilis and Pseudomonas fluorescens against Meloidogyne incognita, Fusarium oxysporum, and Rhizoctonia solani 🌱
  2. Bio-efficacy of phytoextracts and oil cakes on Macrophomina phaseolina causing stem rot disease of jute, Corchorus spp. 🌿
  3. Host plant resistance in cultivated jute and its wild relatives towards jute hairy caterpillar Spilosoma obliqua (Lepidoptera: Arctiidae) 🦋
  4. Eco-friendly management of major diseases in jute (Corchorus olitorius L.) 🌾
  5. Evaluation of stem rot disease in jute (Corchorus olitorius) germplasm caused by Macrophomina phaseolina (Tassi) Goid 🍂
  6. Problems and prospects of pest management in jute and allied fibre crops 🌱
  7. Simultaneous detection of potato viruses A and M using CP gene-specific primers in an optimized duplex RT-PCR 🥔
  8. Detection of Mesta yellow vein mosaic virus (MeYVMV) in field samples by a loop-mediated isothermal amplification reaction 🌾
  9. In vitro screening of white Jute (Corchorus capsularis L) against salinity stress 💧
  10. Evaluation of efficacy of different bioagents and fungicides against Rhizoctonia solani (Kuhn) ⚗️

Conclusion:

Dr. P. N. Meena is an exceptional researcher with a proven track record of developing innovative solutions for plant disease management, particularly in the horticultural and fibre crop sectors. Her work is characterized by both depth and breadth, making a significant impact on the agricultural community. The strengths of her research, leadership, and recognition make her a strong contender for the Research for Best Paper Award. However, future directions could involve expanding collaborations into cutting-edge technologies and increasing visibility through international journals. Overall, Dr. Meena’s work stands out for its scientific rigor, practical applications, and contribution to sustainable agriculture.